Patients with overexpression of SLFN11, which included approximately 45% of metastatic CRPC patients and 25% primary PCa, treated with platinum chemotherapy showed a longer radiographic PFS and a decline of PSA by 50% or more, while no difference in OS was seen [30]. Here, SLFN11 is linked to posterior cortical atrophy.